BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

How Much Money To Invest Now BioNTech stock is building a consolidation with a 131.49 buy point. See if the biotech stock can clear the breakout price in volume at least 40% higher than normal.

How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up ...

The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday ...

This is the main Biontech stock price chart and current quotes. You can find more details about BNTX stock by going to one of our multiple sections under this page such as historical data ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

BioNTech is a Germany-based biotechnology ... It is calculated by dividing the stock price by earnings per share. Value investors look for low P/E ratios that are 15 or lower.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...